Patent review identifies 15+ CHK1 inhibitors in clinical trials, suggesting potential for cancer treatment advancement.
Introduction Checkpoint kinase 1 (CHK1), a serine/threonine kinase, plays an important role in the DNA damage response (DDR), such as cell cycle checkpoints, DNA repair, transcriptional regulation, and apoptosis inhibition. CHK1 has emerged as a promising therapeutic target for cancer treatment. To date, over fifteen CHK1 inhibitors have advanced into clinical trials, yet none have been approved for marketing.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: